Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 16/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845340 | 1.00 | PRLHR (0.35) | PRLHRCYP1A2CYP2D6CYP2C9ITGB2 | |
| SCHEMBL22845357 | 0.91 | PRLHR (0.35) | PRLHRCYP1A2CYP2D6CYP2C9ALDH1A1 | |
| SCHEMBL24173491 | 0.90 | ITGB2 (0.33) | PRLHRCYP1A2CYP2D6CYP2C9ITGB2 | |
| SCHEMBL22845323 | 0.89 | MTHFD2 (0.34) | MTHFD2ALDH1A1 | |
| SCHEMBL22845388 | 0.87 | PREP (0.35) | PRLHRITGB2ICAM1ITGALMTHFD2 | |
| SCHEMBL24483838 | 0.85 | HDAC1 (0.35) | ITGB2ICAM1ITGALMTHFD2ALDH1A1 | |
| SCHEMBL22830564 | 0.85 | TP53 (0.32) | PRLHRITGB2ICAM1ITGALMAPT | |
| SCHEMBL22845373 | 0.84 | TP53 (0.35) | MTHFD2ALDH1A1MAPT | |
| SCHEMBL22845506 | 0.84 | S1PR2 (0.34) | ALDH1A1MAPT | |
| SCHEMBL22845519 | 0.82 | MTHFD2 (0.35) | CYP1A2CYP2C9MTHFD2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | PRLHR 2579/4885CYP1A2 86/4885CYP2D6 81/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | PRLHR 2579/4885CYP1A2 86/4885CYP2D6 81/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | PRLHR 2579/4885CYP1A2 86/4885CYP2D6 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.